Publication details
Inhibitory tyrozinkináz v léčbě CML - která dávka je ta pravá?
| Title in English | Tyrosine kinase inhibitors in the treatment of CML - which dose is right? |
|---|---|
| Authors | |
| Year of publication | 2023 |
| MU Faculty or unit | |
| Citation | |
| Description | A prospective phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitor withdrawal after prior two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission The HALF clinical trial is designed as a prospective, multicenter, nonrandomized, open-label phase II study to assess the efficacy and safety of tyrosine kinase inhibitor withdrawal after a prior two-step dose reduction in patients with chronic myeloid leukemia in deep remission. The clinical evaluation of HALF could contribute to the formulation of a new disease management strategy for patients achieving sustained remission with the potential for wider benefits not only for the patients themselves, but also for the healthcare system. |